InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 173477

Thursday, 04/17/2014 11:22:40 PM

Thursday, April 17, 2014 11:22:40 PM

Post# of 345694
Alan Schroit : Peregrine Pharmaceuticals KOL :

S. Banafsheh Mirnikjoo, Krishnakumar Balasubramanian, and Alan J. Schroit - M. D. Anderson Cancer Center, University of Texas

REGULATION OF PHOSPHATIDYLSERINE ASYMMETRY BY CA2+-DEPENDENT
MEMBRANE FUSION DURING APOPTOSIS OF BREAST CANCER CELLS

In summary our data indicate that extensive membrane rearrangements and inter-organelle fusion occur through a mechanism that involves specific elevations in cytosolic Ca2+ levels during apoptosis that results in the reorientation of PS from the cells inner-to-outer membrane leaflet. This work provides the basis toward understanding the molecular events that regulate the elimination of errant cells. The identification of candidate molecules that regulate PS externalization will facilitate the development of specific targeted
therapeutic strategies.


http://cdmrp.army.mil/bcrp/era/abstracts2008/bc051268.pdf

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News